APOE and Mental deterioration: In EOAD, multivariable analyses showed that APOE ε4 carriers demonstrated slower cognitive decline in general cognitive function (MMSE and CDR-SB, P = .011 and .010), language (P = .010), memory (P = .027), and frontal-executive function (P = .002) than did APOE ε4 non-carriers.